Boston Scientific (BSX)

NYSEHealth CareMedical DevicesSnapshot 2026-07-08

$44.80-1.09%

Close 2026-07-08 · 1-day change

Reading BSX? This analysis is rebuilt every market day. Get it tracked free. No credit card.

Track BSX free→

The thesis

The standing, falsifiable read: what has to stay true, and what would break it.

Compounder

The bull case

Boston Scientific grows sales about 8% a year with strong cardiovascular gains. Profit margins stay near 13.5%. The company buys back stock and invests in new products. Recent earnings beats show execution despite challenges.

The bear case

Product recalls and weaker outlook threaten sales growth. Guidance cuts and negative news create risks. Operational efficiency is mixed, pressuring profit margins and cash flow.

What's priced in

The price is about 44% below our fair value near $81. Analysts expect about 9% revenue growth. The market prices in risks from recent guidance cuts and product issues, which we partially agree with.

What has to stay true

Cardiovascular segment grows at least 10% annuallyUnder Pressure
Competitive Moatprimary>=10% YoY growth · FY26 (qualitative)
Breaks if: Cardiovascular segment growth falls below 7% next year
Are they delivering?On Track this quarter· 1 tracked commitment
- Expand cardiovascular segmentProduct
  Enhance the cardiovascular segment through product innovation and market penetration.
  On Track
  Stated in 2 of last 2 quarters. Cardiovascular segment grew 13.5% in 2026-Q1, following an 18.2% increase in 2025-Q4. This consistent growth reflects management's focus on product innovation and market penetration in the cardiovascular space.
Net sales grow at least 7% annuallyUnder Pressure
Revenue Growthprimary>=7% YoY revenue growth · FY26 (guidance)
Breaks if: YoY revenue growth falls below 5% next year
Are they delivering?On Track this quarter· 1 tracked commitment
- Drive net sales growthGrowth
  Focus on increasing net sales through strategic initiatives and market expansion.
  On Track
  Stated in 2 of last 2 quarters. Net sales grew from $4.663 billion in 2025-Q1 to $5.203 billion in 2026-Q1, indicating a strong growth trajectory. Management's focus on strategic execution and pipeline advancement is delivering results.
Improve operational efficiency through cost managementUnder Pressure
Management ExecutionsupportingOperational efficiency improves steadily · next 4 quarters (qualitative)
Breaks if: No improvement in operational efficiency metrics over next year
Are they delivering?Mixed this quarter· 1 tracked commitment
- Enhance operational efficiencyCost
  Improve operational efficiency through cost management and process optimization.
  Mixed
  CEO/CFO:
Operating margin near 13.5%Intact
Marginprimary~13.5% operating margin · FY25 (guidance)
Breaks if: Operating margin falls below 12% next year

Standing thesis, reviewed periodically — not a price target or advice.

Read the full Outlook — the long-form 1–3 year hold read

Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.